Sinovac and Sinopharm, the two Chinese manufacturers that combined have exported hundreds of millions of doses all over the world, say they're are considering combining theirEarlier this month, the head of China's Center for Disease Control, Gao Fu, said that current vaccines offer low protection against theGao later tried to walk back his comments, saying he was talking in general about improving vaccine efficacy.
The company, a subsidiary of state-owned Sinopharm, made two inactivated COVID-19 vaccines and a third in clinical trials. Sequential immunization means mixing different vaccines and it is a strategy that could boost efficacy rates, said Ashley St. John, an immunologist at Duke-NUS Medical School in Singapore.
Sinopharm's vaccines, from its Beijing Institute of Biological Products and the Wuhan Institute of Biological Products, are 79% and 72% effective, respectively, the company said. It has not publicly revealed more data from the final stage of its clinical trials.
Of course they are